Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All Trans Retinoic Acid: A Monocentric Experience. Coagulopathy in APL treated with ATRA and Arsenic Trioxide.

Main Article Content

Francesco Autore
a:1:{s:5:"en_US";s:39:"Fondazione Policlinico A. Gemelli IRCCS";}

Patrizia Chiusolo
Federica Sora'
Luca Laurenti
Livio Pagano
Andrea Bacigalupo
Valerio De Stefano
Simona Sica

Keywords

acute promyelocytic leukaemia, all-transretinoic acid, arsenic trioxide., coagulopathy, Thrombosis

Abstract

No abstract


 

Downloads

Download data is not yet available.


Abstract 754
PDF Downloads 830
HTML Downloads 358

Article Sidebar

PDF HTML
Published
Jan 1, 2023
DOI https://doi.org/10.4084/MJHID.2023.009

Article Details

How to Cite

Autore, F. (2023) “Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All Trans Retinoic Acid: A Monocentric Experience. : Coagulopathy in APL treated with ATRA and Arsenic Trioxide”., Mediterranean Journal of Hematology and Infectious Diseases, 15(1), p. e2023009. doi: 10.4084/MJHID.2023.009.
Issue
Vol. 15 No. 1 (2023): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Scientific Letters
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.